MBX Biosciences, Inc. Board of Directors

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Mr. Peter Kent Hawryluk MBA

Mr. Peter Kent Hawryluk MBA

CEO, President & Director

Ms. Michelle Graham

Ms. Michelle Graham

Chief Human Resources Officer

Dr. Michael A. Dorato DABT, Ph.D.

Dr. Michael A. Dorato DABT, Ph.D.

Sr. Vice President of Discovery & Non-Clinical Development

Mr. Richard B. Bartram CPA

Mr. Richard B. Bartram CPA

Chief Financial Officer

Dr. Salomon Azoulay

Dr. Salomon Azoulay

Chief Medical Officer

Mr. Matt Gambino

Mr. Matt Gambino

Vice President of Marketing

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.